Key Takeaways QGEN partners with Tracer and Foresight to advance MRD testing in oncology clinical trials. New alliances support decentralized, non-invasive diagnostics using QIAGEN's QIAcuity dPCR and ctDNA tests. The partnerships aim to broaden clinical access and enhance QGEN's leadership in personalized cancer care.QIAGEN N.V. (QGEN) announced the expansion of its oncology diagnostics portfolio with two strategic partnerships. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics ...

BOULDER, Colo., Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to develop and commercialize a kit-based version of Foresight's CLARITY™ assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological malignancies.Th ...

Core Insights - Myriad Genetics announced new clinical data from the MONSTAR-SCREEN-3 study, demonstrating the effectiveness of its ultra-sensitive Precise™ MRD Test in detecting circulating tumor DNA (ctDNA) across various cancer types [1][2] - The study achieved 100% baseline detection of ctDNA and found that 60% of patients testing positive one month post-surgery had ctDNA levels only detectable via the ultra-sensitive test [2] Study Findings - The MONSTAR-SCREEN-3 study involved approximately 1,200 patients across more than 20 cancer types, focusing on the application of MRD monitoring using Precise MRD [3] - The study aims to provide high-quality clinical evidence for the broad application of MRD testing, particularly in low-shedding tumors [3] - ctDNA levels are assessed at multiple time points, including diagnosis, post-neoadjuvant therapy, and post-surgery, with follow-ups every 3-6 months for at least two years [3] Test Details - Myriad's Precise MRD test is a tumor-informed, whole-genome sequencing (WGS)-based test that monitors hundreds to thousands of tumor-specific variants, offering exceptional sensitivity in ctDNA detection [4][5] - The test can detect tumor fractions as low as 0.0001% (1 part per million) and has shown a clinically meaningful lead time in detecting recurrence compared to imaging [5] Clinical Implications - The results indicate that ctDNA status after neoadjuvant treatment is strongly associated with pathological response, highlighting the potential for personalized treatment strategies [2][5] - The enhanced sensitivity of the Precise MRD test allows for better monitoring and treatment planning for patients with low-shedding tumors, such as breast and renal cancers [2][4]

汴京街头闪现新物种、皮卡来"电"上演神救场、唐小妹穿越千年与AI对话……5月30日，郑州日产携手河南卫视《唐宫夜宴》《天庭潮音》 IP，以"端午奇妙游"国潮盛宴，正式宣告了旗下"智能电混新一代"Z9 GE PHEV的上市。新车提供60km、135km两种版本，七款配置可选，官方 指导价15.69万-21.99万元。 郑州日产与河南卫视《端午奇妙游》强强联手，首次采用MR混合现实技术，将国潮文化、皮卡全场景、电混科技串联，为观众们带来了一场沉浸式 的奇幻之旅。 当潮不让 Z9 GE PHEV秒变"移动电站" 活动在"当潮不让"时空音乐会中拉开帷幕，传统乐器与现代电子、国风流行与抒情歌曲轮番上演，将音乐会气氛推向顶点。在《永不失联的爱》的歌 声中，舞台的音响突然"罢工"，在此起彼伏的惊叹声中，Z9 GE PHEV以黑科技"救场"，它的对外放电功能秒变"移动电站"，迅速连上音响设备，音乐声 再次响起，也瞬间点燃了游人们的热情。 Z9 GE PHEV特别来"电"，对外放电功能支持行车放电、驻车放电、锁车放电。移动的潮玩营地，秒变露天影院和音乐唱吧；出门带上小冰箱和茶 具，远离繁华也能随时来杯冰饮或热茶；烧烤炉、咖啡机 ...

Company Overview - Moderna is focused on building a diverse portfolio of products utilizing mRNA technology, targeting areas such as infectious diseases, cancer, rare diseases, and autoimmune diseases [3]. Strategic Priorities - The company has outlined three main priorities for the year: 1. To drive sales through approved products, specifically COVID-19 and RSV vaccines [3]. 2. To launch new products to diversify and grow the top line, with up to 10 launches planned over the next few years and several Biologics License Applications (BLAs) already filed [4]. 3. To resize the company from a cost perspective in response to the transition from pandemic-related sales [4].

Moderna (MRNA) FY 2025 Conference May 29, 2025 10:00 AM ET Speaker0 Sure. Speaker1 Fantastic. So I am thrilled to be here today with Stephane Pansell from Moderna. My name is Courtney Breen. I am The U. S. Biopharma Analyst here at Bernstein. Before we dive into the Q and A, I will give Stephane the opportunity to give us some context to where Moderna is at, and then we'll dive in. I've got a long, long list of questions, and we I'm sure we won't get through all. For as a reminder, and I think if you have a ...

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility: Credit: Pixabay/CC0 Public Domain After Tennant figured out how to keep its plants open during the pandemic, it had a second problem to solve. The company's designers aren't all in the same place. Neither are its customers, and sharing pen-and-paper designs isn't easy on a video call.Video game technology gave the company a wa ...

WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed’s unique position as the world’s only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device ...

编号：2025-003 | 投资者关系活动 | √特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他 （电话会议） | | 参与单位名称及 | 西部证券、摩根基金、人保养老、华泰柏瑞、万家基金、华 | | 人员姓名 | 泰资管、长盛基金、城旸投资、工银瑞信、宏利基金、招商 | | | 基金、西南证券 | | 时间 | 年 月 日-5 月 日 2025 5 22 29 | | 地点 | 电话会议 | | 上市公司接待人 | 公司高级副总裁盛海先生、董事会秘书李坤先生、副总裁窦 | | 员姓名 | 颖辉先生、学术总监程联胜先生 | | | 公司与投资者就相关问题进行了沟通，整理如下： | | | 问 年度的经营目标？ 1：公司 2025 | | | 答：2025 年公司的整体经营目标是实现恢复性增长，继 | | 投资者关系活动 | 续保持公司稳定健康发展的态势。公司将积极加强学术推 | | 主要内容介绍 | 广，提升水针的销售占比，推动生长激素的恢复性增长；中 | | | 药板块自去年 ...

GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy. Spero’s stock price was up 245.89% at last check Wednesday following the news. The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) based on a planned interim analysis of data from 1,690 patients enrolled in the study. Also Read: GSK To Buy Phase-3 Ready Liver Di ...